Frailty stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma – the FRAIL-M study

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • McQuilten, Zoe (Chief Investigator (CI))
  • Wood, Erica Michelle (Chief Investigator (CI))
  • Reynolds, John (Chief Investigator (CI))
  • Quach, Hang (Chief Investigator (CI))
  • De Abreu Lourenco, Richard (Chief Investigator (CI))
  • King, Madeleine (Chief Investigator (CI))
  • Mollee, Peter (Chief Investigator (CI))
  • Hubbard, Ruth E. (Chief Investigator (CI))

Project: Research

Short titleFRAIL-M
StatusActive
Effective start/end date3/01/1930/09/23

Funding

  • Medical Research Future Fund: AUD1,682,835.68